A Gallbladder Carcinoma Patient With Pseudo-Progressive Remission After Hydrogen Inhalation.
Jibing Chen, Feng Mu, Tianyu Lu, Yangyang Ma, Duanming Du, Kecheng Xu · OncoTargets and therapy · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In CASE PRESENTATION: A 72-year-old female patient presented with metastatic gallbladder cancer and underwent symptomatic treatment combined with hydrogen therapy, the patient has undergone hydrogen treatment for 10 months to date, and her condition has further improved. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in CASE PRESENTATION: A 72-year-old female patient presented with metastatic gallbladder cancer and underwent symptomatic treatment combined with hydrogen therapy. The patient has undergone hydrogen treatment for 10 months to date, and her condition has further improved.
What the Researchers Studied
The researchers studied CASE PRESENTATION: A 72-year-old female patient presented with metastatic gallbladder cancer and underwent symptomatic treatment combined with hydrogen therapy.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 10 months. The patient has undergone hydrogen treatment for 10 months to date, and her condition has further improved. The authors concluded that this is the first report of pseudo-progression followed by sustained remission after hydrogen inhalation.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a case report. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as case report with human clinical evidence. The research population or model was CASE PRESENTATION: A 72-year-old female patient presented with metastatic gallbladder cancer and underwent symptomatic treatment combined with hydrogen therapy. The reported sample size was 55. The reported treatment duration was 10 months.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.